Antacids Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Type (Tablet, Liquid, others), By End-use (Retail Pharmacy, Hospital Pharmacy, Online Pharmacy), By Region & Competition, 2021-2031F

The global antacids market is projected to expand from USD 7.21 billion in 2025 to USD 9.13 billion by 2031, achieving a compound annual growth rate of 4.01%. Antacids are pharmaceutical products designed to neutralize stomach acid, offering relief from symptoms like heartburn, acid reflux, and indigestion. This market's growth is primarily driven by the increasing occurrence of gastrointestinal issues, often linked to sedentary habits and unhealthy diets, combined with a rising elderly population more susceptible to digestive problems. Moreover, the market gains significantly from consumers' widespread use of readily available over-the-counter treatments for minor health issues, bypassing the need for a doctor. Data from the Proprietary Association of Great Britain in 2024 showed that 89% of adults were confident in using nonprescription medicines for symptom management, highlighting the crucial role of self-care in boosting market demand.

However, a key obstacle to the global antacids market's expansion is the increasing public awareness of potential negative side effects associated with long-term use, such as kidney problems and electrolyte imbalances. These safety concerns have intensified regulatory oversight and may encourage consumers to explore other treatments or lifestyle changes, thus potentially limiting the long-term growth prospects of conventional antacid products.

Market Driver

The rising prevalence of Gastroesophageal Reflux Disease (GERD) is a core driver for the global antacids market, closely linked to the increase in sedentary lifestyles and poor dietary habits. As acid-related conditions become more common, the need for immediate symptom relief from acid-neutralizing medications has soared, prompting manufacturers to boost production. A November 2024 article from the National Institutes of Health, "Global burden and temporal trends in GERD," reported approximately 825.6 million prevalent GERD cases globally. This significant public health trend ensures ongoing demand for antacid medications. This expanding patient demographic, largely influenced by an aging population and rising obesity rates, requires continuous treatment, thereby securing the market's long-term revenue growth.

Simultaneously, a growing consumer preference for self-medication is substantially fueling market expansion, with individuals increasingly choosing readily available over-the-counter (OTC) treatments for digestive issues without needing professional medical advice. This trend is bolstered by the broad availability of established brands and convenient digital shopping platforms, enabling consumers to manage minor symptoms independently. Haleon's Q3 2024 Trading Statement, from October 2024, noted a 5.9% organic revenue increase in its Digestive Health division, largely due to double-digit growth in the Tums brand, confirming this move towards self-directed health management. Further supporting this industry momentum, Sanofi's Consumer Healthcare unit reported a 9.6% sales growth in the second quarter of July 2024, underscoring the strong financial performance of the digestive wellness sector.

Market Challenge

Increasing awareness regarding the potential adverse effects of prolonged antacid consumption, notably renal complications and electrolyte imbalances, presents a significant hurdle for the global market. As consumers become more informed about health, the link between ongoing antacid use and kidney stress discourages the routine, preventive use of these products. This heightened scrutiny shifts the perception of antacids from a harmless daily item to a medication requiring careful consideration, leading users to buy them less often or switch to lifestyle adjustments and doctor-prescribed alternatives, consequently diminishing recurring revenue.

This market slowdown is exacerbated by declining consumer confidence in self-managing health issues when faced with potential safety risks. A 2025 report from the Proprietary Association of Great Britain showed that the percentage of adults first consulting pharmacists for self-treatable conditions dropped to 51%, indicating a notable decrease in reliance on nonprescription options. This pattern suggests that concerns about health complications are pushing a considerable segment of the market towards medical professionals instead of over-the-counter remedies, thereby hindering volume growth in the traditional antacid sector.

Market Trends

The emergence of innovative delivery formats, notably gummies and soft chews, is transforming consumer buying patterns in the global antacids market, as users increasingly value sensory experience and ease of use over conventional chalky tablets. Manufacturers are actively expanding their product ranges with non-medicinal options that resemble confectionery, enhancing patient compliance and appealing to younger consumers who see digestive well-being as integral to their lifestyle. This approach has effectively maintained category value; Haleon's Q3 2025 Trading Statement from October 2025 reported a 2.1% organic revenue growth in its Digestive Health division, specifically attributing it to successful product innovations like TUMS Gummy Bites Plus. This development necessitates competitors to invest in improving flavor and texture to distinguish their products in a competitive retail landscape.

Simultaneously, there is an increasing demand for herbal and plant-based antacid alternatives, fueled by the "clean label" movement and growing consumer distrust regarding the long-term safety of synthetic chemicals. This trend has elevated botanical ingredients such as peppermint and chamomile from specialized remedies to widely accepted therapeutic choices, leading major pharmaceutical companies to acquire or develop natural product lines to retain health-conscious clientele. The financial effects of this shift are clear; Bayer's Quarterly Statement Q3 2025 from November 2025 indicated a 6.5% increase in Digestive Health sales on a currency- and portfolio-adjusted basis, significantly boosted by the strong performance of the herbal brand Iberogast. As a result, the market is observing a divide where natural formulations attract higher prices while posing a challenge to the established dominance of traditional proton pump inhibitors.

Key Market Players

• GlaxoSmithKline plc
• Bayer AG
• Boehringer Ingelheim International GmbH
• Dr. Reddy's Laboratories Ltd.
• Sanofi SA
• Reckitt Benckiser Group plc
• Sun Pharmaceuticals Ltd.
• Takeda Pharmaceutical Company Limited
• Pfizer Inc.
• Procter & Gamble Co.

Report Scope

In this report, the Global Antacids Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Antacids Market, By Type

• Tablet
• Liquid
• others

Antacids Market, By End-use

• Retail Pharmacy
• Hospital Pharmacy
• Online Pharmacy

Antacids Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Antacids Market.

Available Customizations:

Global Antacids Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).